drugset

drugset / Trial / NCT07344051

A Phase II Study of QLS12010 Capsules in Adults With Moderate to Severe Atopic Dermatitis

NCT07344051 ↗

Phase 2 Not yet recruiting 160 enrolled Qilu Pharmaceutical Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This trial was designed to evaluate the efficacy and safety of QLS12010 Capsules in adults with moderate-to-severe atopic dermatitis.

Timeline

Start: 2026-04-05
Primary completion: 2027-09
Completion: 2027-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	QLS12010	Unknown	—	Oral

Indications